Ideaya Biosciences Inc (IDYA)
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
Aclarion Appoints Greg Gould as Chief Financial Officer
Hyphens Notification - Evolve Capitals Equity Research - 1H25: Near Term Performance Likely to Remain Subdued Before Modest Recovery
Evolve Capital’s Equity Research – Near Term Performance Likely to Remain Subdued Before Modest Recovery
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Harnessing Human Potential to Power Vaccine Innovation
Gamescom 2025 Recap: Biggest Announcements and Highlights
AI in Game Design: Smarter NPCs, Dynamic Storytelling, and Procedural Worlds
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm